Plain-English translation of NCT07479485 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called , given alongside other established cancer treatments, to see if it can help people with advanced liver cancer. Researchers want to understand whether this combination is safe and whether it helps slow or shrink tumors. The trial will enroll about 160 patients across multiple hospitals.
Advanced liver cancer is a serious disease with limited treatment options. This medication is designed to work with the immune system in a new way, and early research suggests it might work better when combined with other proven cancer therapies. This trial will test whether that combination approach actually helps patients.
You likely qualify if…
You likely don't qualify if…
You would receive the medication intravenously (through an IV) at a hospital or clinic, typically in combination with one or two other cancer drugs depending on which treatment group you are assigned to. You would have regular visits to receive infusions, undergo blood tests and scans to monitor how the cancer is responding, and report any side effects you experience. The study will track your safety and how well the treatment works over time.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China